Advertisement

Rheumatology International

, Volume 33, Issue 5, pp 1327–1331 | Cite as

Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life

  • Pelin OktayogluEmail author
  • Serda Em
  • Mehmet Tahtasiz
  • Mehtap Bozkurt
  • Demet Ucar
  • Levent Yazmalar
  • Kemal Nas
  • İbrahim Yardımeden
  • Figen Cevik
  • Yusuf Celik
  • Nuriye Mete
Original Article

Abstract

This study was carried out to determine the serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis (AS) and to evaluate its correlation with disease activity and quality of life. According to our knowledge, it is the first trial evaluating HMGB1 levels in AS. Serum samples of 30 patients (18 males and 12 females) with AS and 29 healthy controls (HC) (15 females and 14 males) were collected. HMGB1 levels were measured by enzyme-linked immunosorbent assay, activity of disease was assessed according to the Bath AS Disease Activity Index (BASDAI), and functional status of patients was evaluated with Bath AS Functional Index (BASFI). Modified Schober, chest expansion values and AS Quality of Life Questionnaire (ASQoL) scores were noted. The serum levels of HMGB1 were obtained significantly increased in AS patients compared to HC (p < 0.05). There was no significant correlation between HMGB1 levels and ESR (p > 0.05), and CRP (p > 0.05) values. BASDAI, BASFI and ASQoL scores were also not correlated with serum levels of HMGB1 (p > 0.05). Our results suggest that HMGB1 might play an important role in the pathogenesis of AS; however, it seems not to be a good candidate for reflecting disease activity, functional abilities and the quality of life in patients with AS; on the other hand, the increased levels of HMGB1 in patients may open a new dimension for targeting this cytokine as a new therapy option in AS.

Keywords

Ankylosing spondylitis High mobility group box protein 1 Disease activity Quality of life 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Gardner DL (1992) Reactive and postinfective arthritis and seronegative spondyloarthropathy. In: Gardner DL (ed) Pathological basis of the connective tissue diseases. London, pp 763–795Google Scholar
  2. 2.
    Pöllänen R, Sillat T, Pajarinen J et al (2009) Microbial antigens mediate HLA-B27 diseases via TLRs. J Autoimmun 32:172–177PubMedCrossRefGoogle Scholar
  3. 3.
    Cruickshank B (1956) Lesions of cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol 71:73–84PubMedCrossRefGoogle Scholar
  4. 4.
    Ball J (1971) Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 30:213–223PubMedCrossRefGoogle Scholar
  5. 5.
    Sieper J, Appel H, Braun J et al (2008) Critical appraisal of assessment of structural damage in ankylosing spondylitis. Arthritis Rheum 58:649–656PubMedCrossRefGoogle Scholar
  6. 6.
    Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1–5PubMedCrossRefGoogle Scholar
  7. 7.
    Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10:209PubMedCrossRefGoogle Scholar
  8. 8.
    Taniguchi N, Kawahara K, Yone K et al (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48:971–981PubMedCrossRefGoogle Scholar
  9. 9.
    Chun yun ma C, MaJiao Y, Zhang J et al (2012) Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int 32:395–402CrossRefGoogle Scholar
  10. 10.
    Yu M, Wang H, Ding A et al (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174–179PubMedCrossRefGoogle Scholar
  11. 11.
    Park JS, Gamboni-Robertson F, He Q et al (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290:917–924CrossRefGoogle Scholar
  12. 12.
    Anderson U, Wang H, Palmblad K et al (2000) High mobility group 1 protein (HMG 1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565–570CrossRefGoogle Scholar
  13. 13.
    Bal A, Unlu E, Bahar G et al (2007) Comparison of serum IL-1, sIL-2R, IL-6 and TNF- alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26:211–215PubMedCrossRefGoogle Scholar
  14. 14.
    Gratacos J, Collado A, Fiella X et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheum 33:927–931CrossRefGoogle Scholar
  15. 15.
    Taniguchi N, Yoshida K, Ito T et al (2007) The stage specific secretion of HMGB1 in cartilage regulates endochondral ossification. Mol Cell Biol 27:5650–5663PubMedCrossRefGoogle Scholar
  16. 16.
    Yang J, Shah R, Robling AG, Templeton E et al (2008) HMGB1 is a bone-active cytokine. J Cell Physiol 214:730–739PubMedCrossRefGoogle Scholar
  17. 17.
    Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291PubMedGoogle Scholar
  18. 18.
    Akkoc Y, Karatepe AG, Akar S et al (2005) A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int 25:280–284PubMedCrossRefGoogle Scholar
  19. 19.
    Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMedGoogle Scholar
  20. 20.
    Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ et al (2003) Development of ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26PubMedCrossRefGoogle Scholar
  21. 21.
    Duruoz T, Doward L, Cerrahoglu L et al (2008) Translation and validation of the Turkish version of the ankylosing spondylitis quality of life (ASQoL) Questionnaire. Abstract Book, EULARlGoogle Scholar
  22. 22.
    Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342PubMedCrossRefGoogle Scholar
  23. 23.
    Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499–505PubMedCrossRefGoogle Scholar
  24. 24.
    Braun J, van den Berg R, Baraliakos X et al (2010) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896–904CrossRefGoogle Scholar
  25. 25.
    Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251PubMedCrossRefGoogle Scholar
  26. 26.
    Yang H, Wang H, Tracey KJ (2001) HMG-1 rediscovered as a cytokine. Shock 15:247–253PubMedCrossRefGoogle Scholar
  27. 27.
    Andersson U, Erlandsson-Harris H (2004) HMGB1 is a potent trigger of arthritis. J Intern Med 255:344–350PubMedCrossRefGoogle Scholar
  28. 28.
    Assassi S, Reveille JD, Arnett FC et al (2011) Whole-blood gene expression profiling in ankylosing spondylitis shows upregulation of toll-like receptor 4 and 5. J Rheumatol 38:87–98PubMedCrossRefGoogle Scholar
  29. 29.
    Ek M, Popovic K, Harris HE et al (2006) Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum 54:2289–2294PubMedCrossRefGoogle Scholar
  30. 30.
    Ahn JK, Cha HS, Bae EK et al (2011) Extracellular high-mobility group box 1 is increased in patients with Behçet’s disease with intestinal involvement. J Korean Med Sci 26:697–700PubMedCrossRefGoogle Scholar
  31. 31.
    Liu B, Guo CY, Liu WQ et al (2005) The value of erythrocyte sedimentation rate and C-reactive protein in evaluating disease activity in ankylosing spondylitis. Zhonghua Nei Ke Za Zhi 44:566–569PubMedGoogle Scholar
  32. 32.
    Yildirim K, Erdal A, Karatay S et al (2004) Relationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med J 97:350–353PubMedCrossRefGoogle Scholar
  33. 33.
    Spoorenberg A, van der Heijde D, de Klerk E et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26:980–984PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Pelin Oktayoglu
    • 1
    Email author
  • Serda Em
    • 1
  • Mehmet Tahtasiz
    • 1
  • Mehtap Bozkurt
    • 1
  • Demet Ucar
    • 1
  • Levent Yazmalar
    • 1
  • Kemal Nas
    • 1
  • İbrahim Yardımeden
    • 2
  • Figen Cevik
    • 3
  • Yusuf Celik
    • 4
  • Nuriye Mete
    • 5
  1. 1.Department of Physical Medicine and Rehabilitation, Faculty of MedicineDicle UniversityDiyarbakirTurkey
  2. 2.Department of Physical Medicine and RehabilitationUniversal HospitalDiyarbakirTurkey
  3. 3.Department of Physical Medicine and RehabilitationDiyarbakir State HospitalDiyarbakirTurkey
  4. 4.Department of Biostatistics, Faculty of MedicineDicle UniversityDiyarbakirTurkey
  5. 5.Department of Biochemistry, Faculty of MedicineDicle UniversityDiyarbakirTurkey

Personalised recommendations